NCT04123366 2026-04-22
MK-7339-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT06082960 2026-04-16
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
Phase 1 Active not recruiting
NCT03917381 2026-04-06
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04589845 2026-04-02
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06873789 2026-03-25
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Active not recruiting
NCT02789228 2026-03-19
REST
Children's National Research Institute
Phase 1 Active not recruiting
NCT03347318 2026-03-19
PROFILING
Fondazione del Piemonte per l'Oncologia
Active not recruiting
NCT03313778 2026-03-04
KEYNOTE-603
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT03448042 2026-02-27
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Phase 1 Active not recruiting
NCT04250155 2026-02-24
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Active not recruiting
NCT02320435 2026-02-12
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07407985 2026-02-12
GK01IIT-TZ03
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Active not recruiting
NCT00777582 2026-01-13
Phase I Comparative Bioavailability Study
AstraZeneca
Phase 1 Active not recruiting
NCT05327946 2025-10-28
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT02498912 2025-07-31
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting